Lumipulse® G β-Amyloid 1-42/1-40 Ratio (Plasma)
Alzheimer's Disease (Amyloid Pathology)
CommercialFDA Cleared, CE Marked
Key Facts
Indication
Alzheimer's Disease (Amyloid Pathology)
Phase
Commercial
Status
FDA Cleared, CE Marked
Company
About Fujirebio Diagnostics
Fujirebio Diagnostics is an R&D-driven innovator and global provider of in vitro diagnostic solutions, with a mission to create new value in healthcare. Its core achievement is pioneering blood-based biomarkers for Alzheimer's disease, including the first FDA-cleared blood test for amyloid pathology. The company's strategy leverages its proprietary Lumipulse® G platform for internal assay development while operating a synergistic CDMO business, reinvesting partnership revenues to fuel a robust pipeline in neurology, oncology, and infectious diseases.
View full company profileTherapeutic Areas
Other Alzheimer's Disease (Amyloid Pathology) Drugs
| Drug | Company | Phase |
|---|---|---|
| Lumipulse® G pTau 217/β-Amyloid 1-42 Ratio (Plasma) | Fujirebio Diagnostics | Commercial |